Geben Sie eine Aktie oder eine Kryptowährung in der Suchleiste an, um eine Zusammenfassung zu erhalten
Royalty Pharma Plc
RPRXRoyalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York. Address: 110 East 59th Street, New York, NY, United States, 10022
Analytics
Zielpreis von Wall Street
40.17 USDKGV
13.52Dividendenrendite
2.59 %Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Schlüsselzahlen RPRX
Dividenden-Analyse RPRX
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–Dividendenwachstum über 5 Jahre
–Kontinuierliches Wachstum
4 JahreAusschüttungsquote 5-Jahres-Durchschnitt
196.40 %Verlauf der Dividende RPRX
Bewertung der Aktie RPRX
Finanzen RPRX
Ergebnisse | 2019 | Dynamik |